Supply Chain

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts how he anticipates the model growing over the next three to five years, especially as global demand and regulatory complexities increase.

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from CGT’s highly specialized operational strategies, particularly in terms of supply chain resilience and adaptability.

In the second part of this roundtable discussion, a panel of key opinion leaders dive into the key risk factors impacting the pharma manufacturing space, and how the industry should aim to address them.

The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.

In the second part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains how recent shifts in FDA leadership, funding constraints, and evolving CMC standards have each played a role in this process.

In the first part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses both the successes and challenges in commercializing cell and gene therapies.

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in biologics.

In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing the strategies that are most effective in ensuring resilience across the global supply chain.

The new system meets the increasing demand for faster, more precise processes that enhance quality while boosting efficiency in the pharma manufacturing industry.

The 200,000 square-foot Madison, WI facility will serve as the flagship location, with capabilities for future growth.

Stay updated on the Drug Supply Chain Security Act as pharma stakeholders prepare for upcoming deadlines and improved data traceability.

Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.

Approaches powered by RWD can clear the way for a greater focus on patient-centered care.

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city to be named at a later date.

In the third part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, shares the ways in which regulations, including DSCSA, are impacting the adoption of smarter packaging technologies across the industry.

In the second part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, describes why this technology is essential for pharmaceutical safety and efficacy.

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

In the first part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, defines the term, and explains how it is helping to combat the growing threat of counterfeit drugs in today’s global supply chain.

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses how uncertainty can help reshape the way organizations prioritize supply chain investments.

In the third part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, comments on the role of automation and GenAI evolving in workforce development.

The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.

In the second part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses the common misconceptions supply chain leaders might have around the term, and why the processes around optimization need to change.

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.